Zhejiang Yangli Pharmaceutical Technology Co., Ltd.

Hangzhou

Oncologygene editingPhase II

Compare Sign in to watch

What changed

Study registered, no phase assigned: Udall Project 1 Aim 4

3mo agoTrial registeredApr 8, 2026Source filing (opens the source filing in a new tab)

Momentum

95no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,413 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Trial
NA registered
Mar 5, 2026
Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency · RECRUITING · sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
ClinicalTrials.gov · NCT07453407 (opens the source filing in a new tab)
Trial
PHASE1 registered
Oct 5, 2025
Hypertension · RECRUITING · sponsor: Zhejiang Yangli Pharmaceutical Technology Co., Ltd. · VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
ClinicalTrials.gov · NCT07254481 (opens the source filing in a new tab)
Trial
PHASE2 registered
Dec 10, 2024
Acute Lymphoblastic Leukemia · RECRUITING · sponsor: Ruijin Hospital · Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
ClinicalTrials.gov · NCT06718244 (opens the source filing in a new tab)
Grant
R01 · $514k · non-dilutive
Jun 1, 2024
NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHOPPIK, DAVID · NEI · award ends Mar 31, 2028 · Determinants of extraocular motor neuron subtype diversity
NIH RePORTER · NIH RePORTER 11099663 (opens the source filing in a new tab)
Grant
R01 · $655k · non-dilutive
Apr 1, 2024
UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, JING HONG · NCI · award ends Mar 31, 2029 · Mechanistic connection between HPV-specific TCRs and therapeutic responses to ICI in HPV+ HNSCC
NIH RePORTER · NIH RePORTER 11056170 (opens the source filing in a new tab)
Grant
R00 · $238k · non-dilutive
Apr 1, 2024
UT SOUTHWESTERN MEDICAL CENTER · PI WANG, JIALIANG · NIAMS · award ends Mar 31, 2027 · Comprehensive investigation of SP7 during the osteoblast-to-osteocyte transition
NIH RePORTER · NIH RePORTER 11179442 (opens the source filing in a new tab)
Grant
R34 · $350k · non-dilutive
Mar 15, 2024
NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHOPPIK, DAVID · NIDA · award ends Aug 31, 2026 · Transformative Optical Imaging of Brain & Behavior in Navigating Genetic Species
NIH RePORTER · NIH RePORTER 11056872 (opens the source filing in a new tab)
Trial
Study registered
Mar 5, 2024
Parkinsons Disease, Deep Brain Stimulation · RECRUITING · sponsor: University of Minnesota · Udall Project 1 Aim 4
ClinicalTrials.gov · NCT05568199 (opens the source filing in a new tab)
Grant
R21 · $193k · non-dilutive
Mar 1, 2024
UNIVERSITY OF ROCHESTER · PI WANG, JINXIN · NIDCD · award ends Feb 28, 2027 · Exploring the mechanism of chemosensory detection of threatening kairomones and associated behavioral responses
NIH RePORTER · NIH RePORTER 11045663 (opens the source filing in a new tab)
Grant
R35 · $394k · non-dilutive
Feb 1, 2024
STATE UNIVERSITY NEW YORK STONY BROOK · PI WANG, JUN · NIGMS · award ends Jan 31, 2029 · Advanced Single-Cell Protein Analysis with Multiplex in Situ Tagging Array Technology
NIH RePORTER · NIH RePORTER 11017811 (opens the source filing in a new tab)
Grant
R01 · $740k · non-dilutive
Dec 1, 2023
RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI WANG, JUN · NIAID · award ends Oct 31, 2028 · Development of 2C inhibitors as broad-spectrum enterovirus antivirals
NIH RePORTER · NIH RePORTER 10991356 (opens the source filing in a new tab)
Grant
R01 · $84k · non-dilutive
Sep 1, 2023
UNIVERSITY OF WASHINGTON · PI HEBERT, MARY F · NICHD · award ends Aug 31, 2027 · PBPK Modeling & Simulation to Predict Transporter-Mediated Drug Secretion into Human Breast Milk
NIH RePORTER · NIH RePORTER 11314961 (opens the source filing in a new tab)
Grant
R01 · $299k · non-dilutive
Aug 1, 2023
UNIVERSITY OF TENNESSEE KNOXVILLE · PI WANG, JIANBIN · NIGMS · award ends Apr 30, 2027 · A genetic model for metazoan programmed DNA elimination
NIH RePORTER · NIH RePORTER 11082484 (opens the source filing in a new tab)
Grant
UH3 · $816k · non-dilutive
Jul 15, 2023
UNIVERSITY OF MINNESOTA · PI WANG, JING · NINDS · award ends Jun 30, 2029 · Thalamic Coordinated Reset Deep Brain Stimulation for Upper Extremity Essential Tremor: Proof of Principle Study
NIH RePORTER · NIH RePORTER 10886836 (opens the source filing in a new tab)
Grant
UH3 · $12k · non-dilutive
Jul 15, 2023
UNIVERSITY OF MINNESOTA · PI WANG, JING · NINDS · award ends Dec 31, 2029 · Thalamic Coordinated Reset Deep Brain Stimulation for Upper Extremity Essential Tremor: Proof of Principle Study
NIH RePORTER · NIH RePORTER 11223028 (opens the source filing in a new tab)
Grant
R01 · $318k · non-dilutive
May 1, 2023
UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, JUNMEI · NIGMS · award ends Feb 28, 2027 · AI-Powered Biased Ligand Design
NIH RePORTER · NIH RePORTER 11037983 (opens the source filing in a new tab)
Grant
R01 · $551k · non-dilutive
Mar 15, 2022
NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NAGEL, KATHERINE · NINDS · award ends Feb 28, 2027 · The Neural Circuit Basis of Olfactory Navigation in Adult Drosophila
NIH RePORTER · NIH RePORTER 10694403 (opens the source filing in a new tab)
Grant
R01 · $625k · non-dilutive
Aug 1, 2021
UNIVERSITY OF MINNESOTA · PI VITEK, JERROLD L · NINDS · award ends Jun 30, 2027 · Neurophysiological Mechanisms Underlying Parkinsonian Motor Signs
NIH RePORTER · NIH RePORTER 11135386 (opens the source filing in a new tab)
Grant
R01 · $624k · non-dilutive
Apr 1, 2021
UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOLODNER, RICHARD D · NCI · award ends Mar 31, 2027 · FEN1-Nuclease-Targeted Therapy for Ewing Sarcoma
NIH RePORTER · NIH RePORTER 11075134 (opens the source filing in a new tab)
Trial
NA registered
Aug 29, 2019
Pregnancy Related, Labor Complication, Cesarean Section; Dehiscence · COMPLETED · sponsor: Ministry of Health, Singapore · Mechanical Dilation of the Cervix in a Scarred Uterus
ClinicalTrials.gov · NCT03471858 (opens the source filing in a new tab)
Grant
R01 · $594k · non-dilutive
Jul 1, 2019
NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NAGEL, KATHERINE · NIDCD · award ends Jun 30, 2029 · Multi-sensory representations for navigation in the central brain of Drosophila
NIH RePORTER · NIH RePORTER 11042260 (opens the source filing in a new tab)
Grant
R01 · $470k · non-dilutive
Sep 15, 2018
EMORY UNIVERSITY · PI WANG, JINHU · NHLBI · award ends Mar 31, 2028 · Characterization of hapln1a positive cells during zebrafish heart regeneration
NIH RePORTER · NIH RePORTER 11063138 (opens the source filing in a new tab)
Grant
R35 · $457k · non-dilutive
May 1, 2018
UNIVERSITY OF WISCONSIN-MADISON · PI WANG, JUE D. · NIGMS · award ends Feb 29, 2028 · The critical roles of (p)ppGpp in homeostasis and antibiotic tolerance in Gram positive bacteria
NIH RePORTER · NIH RePORTER 11035175 (opens the source filing in a new tab)
Grant
IK6 · non-dilutive
Apr 1, 2018
BALTIMORE VA MEDICAL CENTER · PI WANG, JIAN-YING · VA · award ends Mar 31, 2032 · BLRD Research Career Scientist Award Application
NIH RePORTER · NIH RePORTER 11165160 (opens the source filing in a new tab)
Trial
NA registered
Mar 10, 2017
Colorectal Polyp · ENROLLING_BY_INVITATION · sponsor: Kaohsiung Medical University · CBM588 Reduces Colorectal Polyp Recurrence
ClinicalTrials.gov · NCT06855355 (opens the source filing in a new tab)
Grant
R01 · $541k · non-dilutive
Apr 1, 2016
UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KANE, LAWRENCE P. · NCI · award ends Jun 30, 2028 · Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
NIH RePORTER · NIH RePORTER 11141147 (opens the source filing in a new tab)
Grant
R01 · $301k · non-dilutive
Sep 1, 2011
UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI WANG, JUNLING NONE · NIA · award ends Apr 30, 2028 · Rectifying Disparities Associated with Risk Score-Based MTM Eligibility in Enhanced MTM
NIH RePORTER · NIH RePORTER 11085270 (opens the source filing in a new tab)
Grant
P30 · $413k · non-dilutive
Jun 1, 1998
UNIVERSITY OF MINNESOTA · PI WANG, JINHUA · NCI · award ends Jan 31, 2029 · Cancer Informatics Shared Resource
NIH RePORTER · NIH RePORTER 11060097 (opens the source filing in a new tab)
Grant
R01 · $407k · non-dilutive
Jul 1, 1988
UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KOLODNER, RICHARD D · NIGMS · award ends Jun 30, 2027 · Enzymology of Mismatch Repair in Yeast
NIH RePORTER · NIH RePORTER 11110383 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75principal investigator WANG, JINXIN is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator WANG, JUN is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator WANG, JING is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75principal investigator WANG, JUNMEI is named on this company's filings
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the trial record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
Shared principal investigator or founder links the grant record at 0.75grant to an academic institution linked by a shared principal investigator
new_entity links the trial record at 0.28no candidate cleared the review threshold

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Investigators

The principal investigators named on the grants below. Each links to their federal grant record and every other company traced to their work.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Study registered, no phase assigned: Udall Project 1 Aim 4
3mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Udall Project 1 Aim 4
3mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
4mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
4mo agoTrial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: Mechanical Dilation of the Cervix in a Scarred Uterus
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: Mechanical Dilation of the Cervix in a Scarred Uterus
7mo agoTrial completedSource (opens the source filing in a new tab)
Phase I trial registered: VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
7mo agoTrial registeredSource (opens the source filing in a new tab)
Trial now recruiting: VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
7mo agoTrial recruitingSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Neurophysiological Mechanisms Underlying Parkinsonian Motor Signs
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Multi-sensory representations for navigation in the central brain of Drosophila
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Enzymology of Mismatch Repair in Yeast
May 2025Grant renewalSource (opens the source filing in a new tab)
Phase II trial registered: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
May 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1
May 2025Trial recruitingSource (opens the source filing in a new tab)
Study registered, no phase assigned: CBM588 Reduces Colorectal Polyp Recurrence
May 2025Trial registeredSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Determinants of extraocular motor neuron subtype diversity
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH IK6 · BLRD Research Career Scientist Award Application
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.1M · PBPK Modeling & Simulation to Predict Transporter-Mediated Drug Secretion into Human Breast Milk
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.5M · The critical roles of (p)ppGpp in homeostasis and antibiotic tolerance in Gram positive bacteria
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Characterization of hapln1a positive cells during zebrafish heart regeneration
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH P30 · $0.4M · Cancer Informatics Shared Resource
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · A genetic model for metazoan programmed DNA elimination
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH UH3 · $0.0M · Thalamic Coordinated Reset Deep Brain Stimulation for Upper Extremity Essential Tremor: Proof of Principle Study
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · Rectifying Disparities Associated with Risk Score-Based MTM Eligibility in Enhanced MTM
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R00 · $0.2M · Comprehensive investigation of SP7 during the osteoblast-to-osteocyte transition
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Mechanistic connection between HPV-specific TCRs and therapeutic responses to ICI in HPV+ HNSCC
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · The Neural Circuit Basis of Olfactory Navigation in Adult Drosophila
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · FEN1-Nuclease-Targeted Therapy for Ewing Sarcoma
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R34 · $0.3M · Transformative Optical Imaging of Brain & Behavior in Navigating Genetic Species
Mar 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.3M · AI-Powered Biased Ligand Design
Feb 2025Grant renewalSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Exploring the mechanism of chemosensory detection of threatening kairomones and associated behavioral responses
Feb 2025Grant renewalSource (opens the source filing in a new tab)
NIH UH3 · $0.8M · Thalamic Coordinated Reset Deep Brain Stimulation for Upper Extremity Essential Tremor: Proof of Principle Study
Jan 2025Grant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Advanced Single-Cell Protein Analysis with Multiplex in Situ Tagging Array Technology
Jan 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Development of 2C inhibitors as broad-spectrum enterovirus antivirals
Jan 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Peer position

Grant to raise

NA registered

PHASE1 registered

PHASE2 registered

R01 · $514k · non-dilutive

R01 · $655k · non-dilutive

R00 · $238k · non-dilutive

R34 · $350k · non-dilutive

Study registered

R21 · $193k · non-dilutive

R35 · $394k · non-dilutive

R01 · $740k · non-dilutive

R01 · $84k · non-dilutive

R01 · $299k · non-dilutive

UH3 · $816k · non-dilutive

UH3 · $12k · non-dilutive

R01 · $318k · non-dilutive

R01 · $551k · non-dilutive

R01 · $625k · non-dilutive

R01 · $624k · non-dilutive

NA registered

R01 · $594k · non-dilutive

R01 · $470k · non-dilutive

R35 · $457k · non-dilutive

IK6 · non-dilutive

NA registered

R01 · $541k · non-dilutive

R01 · $301k · non-dilutive

P30 · $413k · non-dilutive

R01 · $407k · non-dilutive